The synthesis of new meridianin derivatives substituted at the C-5 position of the 2-aminopyrimidine ring by various aryl groups and substituted or not by a methyl group on the indole nitrogen is described. These compounds were tested for their kinase inhibitory potencies toward five kinases (CDK5/p25, CK1δ/ε, GSK-3α/β, Dyrk1A and Erk2) as well as their in vitro antiproliferative activities toward a human fibroblast primary culture and two human solid cancer cell lines (MCF-7 and PA 1).
Introduction
Meridianins are marine alkaloids isolated and characterized from the south Atlantic tunicate Aplidium meridianum. 1 Meridianins A-G [1] , [2] and [3] ( Fig. 1 ), indole derivatives substituted in the C-3 position by a 2-aminopyrimidine ring, were successfully evaluated for their ability to inhibit various protein kinases 3 and to display antitumour activity. 4 The closely related meriolins, a family of 7-azaindole synthetic meridianin analogues, which exhibit potent kinase inhibitory activities and antiproliferative properties were also described. [5] and [6] Figure 1 . Meridianins A-G and derivatives A-Q described by our group. Since protein kinases are attractive targets for the discovery of biologically active compounds of potential therapeutic interest, our aim is to identify new ATP-competitive kinase inhibitors. Thus, we were recently interested in meridianin derivatives substituted at the C-5 position of the 2-aminopyrimidine ring. In recent papers, we described the synthesis and biological activities of meridianin G derivatives, substituted or not on the indole nitrogen with a methyl group, and bearing various aryl moieties at the C-5 position of the pyrimidine ring (compounds A-H and J-Q, Fig. 1 ). [7] and [8] It was shown that the substitution at this C-5 position and the methylation of the indole nitrogen were critical for either kinase inhibitory potencies or in vitro antiproliferative activities. The meridianin derivatives A-H and K-Q were tested toward a panel of 9 protein kinases (KDR, IGF-1R, c-Met, RET, c-Src, c-Abl, PKA, CDK2/cyclin A and HER-1) and their in vitro antiproliferative activities were examined toward a human fibroblast primary culture and two human solid cancer cell lines (MCF-7 and PA 1). Despite weak kinase inhibitory potencies, compounds G, H, L and M exhibited high in vitro antiproliferative activities toward PA 1 cells. It was found that these compounds do not interfere with PA 1 cell-cycle and may be considered as direct cytolysis or apoptosis inducers. Considering these first biological results, it was of interest to pursue the study with new aryl substituents on the pyrimidine ring in order to identify the substitution pattern providing the highest biological potencies. In this paper, we described the synthesis of new meridianin analogues diversely substituted at the C-5 position of the pyrimidine ring and methylated or not on the indole nitrogen. Moreover these compounds were tested for their kinase inhibitory potencies toward five kinases (CDK5/p25, CK1δ/ε, GSK3α/β, Dyrk1A and Erk2) as well as their in vitro antiproliferative activities toward a human fibroblast primary culture and two human solid cancer cell lines (MCF-7 and PA 1).
Chemistry
Compounds 1-9 were synthesized from brominated derivatives A or J, methylated or not on the indole nitrogen. A and J were prepared according to previously described procedure (Scheme 1).
7 Suzuki crosscoupling was performed using various commercially available arylboronic acids, tetrakis(triphenylphosphine)palladium(0) and sodium carbonate in a H 2 O/EtOH/toluene medium. Compounds 1-9 were obtained in 31−60% isolated yields. Due to purification difficulties, the nonmethylated analogues of compounds 7-9 could not be isolated as pure compounds.
Conclusion
Encouraging preliminary biological evaluation of diversely substituted meridianins led us to synthesize new derivatives. Suzuki cross-coupling could be applied to compounds A or J, for coupling with either aromatic boronic acids bearing both electron donor and electron acceptor substituents or heteroaromatic boronic acids. Surprisingly, the cytotoxic activity of newly synthesised derivatives 1-10 toward PA 1 cells is significantly smaller than that of the previously described compounds G, H, L, M. This could be due to a lower cellular penetration of compounds 1-10 or lower interaction, due to the modification of the aryl moiety, with the cellular target(s) involved in their antiproliferative activity. Compounds G, 1, 3, 5-7 and 10 have shown sub-micromolar inhibition potencies toward some of the kinases tested. The interesting inhibition of Dyrk1A kinase, which is known to be involved in Alzheimer's disease 11 and Down syndrome, 12 leads us to expand our effort in the synthesis of diversely substituted meridianin derivatives as new potential inhibitors of this kinase. 
Kinase preparations and assays
Kinase activities were assayed in Buffer A or C, at 30 °C, at a final ATP concentration of 15 µM. Blank values were subtracted and activities expressed in % of the maximal activity, i.e. in the absence of inhibitors. Controls were performed with appropriate dilutions of DMSO. CDK5/p25 (human, recombinant) was prepared as previously described. [13] and [14] Its kinase activity was assayed in buffer C, with 1 mg histone H1 /ml, in the presence of 15 µM [γ-
33 P] ATP (3,000 Ci/mmol; 10 mCi/ml) in a final volume of 30 µl. After 30 min incubation at 30 °C, 25 µl aliquots of supernatant were spotted onto 2.5 × 3 cm pieces of Whatman P81 phosphocellulose paper, and, 20 s later, the filters were washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters were counted in the presence of 1 ml ACS (Amersham) scintillation fluid. GSK-3αβ (porcine brain, native) was assayed, as described for CDK5/p25 but in Buffer A and using a GSK-3 specific substrate (GS-1: YRRAAVPPSPSLSRHSSPHQSpEDEEE) (pS stands for phosphorylated serine). 15 GS-1 was synthesized by Millegen (Labege, France). CK1δ/ε (porcine brain, native) was assayed as described for CDK5/p25 but using the CK1-specific peptide substrate RRKHAAIGpSAYSITA, 16 obtained from Millegen (Labege, France). Erk2 (rat, recombinant) was assayed as described for CDK5/p25 but using the specific substrate Ets1 (amino acids 1-138) in buffer A. DYRK1A (rat, recombinant, expressed in Escherichia coli as a GST fusion protein) was purified by affinity chromatography on glutathione-agarose and assayed as described for CDK5/p25 using myelin basic protein (1 mg/ml) as a substrate.
In vitro antiproliferative assays 5.2.1. Cell cultures
Stock cell cultures were maintained as monolayers in 75 cm 2 culture flasks in Glutamax Eagle's minimum essential medium (MEM) with Earle's salts supplemented with 10% fetal calf serum, 5 ml 100 mmol/l sodium pyruvate, 5 ml of 100× non-essential amino acids and 2 mg gentamicin base. Cells were grown at 37 °C in a humidified incubator under an atmosphere containing 5% CO 2 .
Survival assays
Cells were plated at a density of 5 × 10 3 cells in 150 µl culture medium in each well of 96-well microplates and were allowed to adhere for 16 h before treatment with tested drug. A stock solution 20 mmol/l of each tested drug was prepared in DMSO and kept at −20 °C until use. Then 50 µl of each tested solution were added to the cultures. A 48 h continuous drug exposure protocol was used. The antiproliferative effect of the tested drug was assessed by the resazurin reduction test.
Resazurin reduction test
Plates were rinsed with 200 µl PBS at 37 °C and emptied by overturning on absorbent toweling. Then 150 µl of a 25 µg/ml solution of resazurin in MEM without phenol red was added to each well. Plates were incubated for 1 h at 37 °C in a humidified atmosphere containing 5% CO 2 . Fluorescence was then measured on an automated 96-well plate reader (Fluoroscan Ascent FL, Labsystem) using an excitation wavelength of 530 nm and an emission wavelength of 590 nm. Under the conditions used, fluorescence was proportional to the number of living cells in the well. The IC 50 , defined as the drug concentration required to inhibit cell proliferation by 50%, was calculated from the curve of concentration-dependent survival percentage, defined as fluorescence in experimental wells compared with fluorescence in control wells, after subtraction of the blank values.
Chemistry
IR spectra were recorded on a Perkin-Elmer Paragon 500 spectrometer in cm −1 ). NMR spectra were performed on a Bruker AVANCE 400 ( 1 H: 400 MHz, 13 C: 100 MHz), chemical shifts δ are noted in ppm and the following abbreviations are used: singlet (s), doublet (d), triplet (t), doublet of doublet (dd), doublet of doublet of doublet (ddd), doublet of triplet (dt), multiplet (m), broad signal (br s). Mass spectra (ESI+) were determined on a high resolution Waters Micro Q-Toff apparatus. Chromatographic purifications were performed on flash silica gel Geduran SI 60 (Merck) 0.040-0.063 mm column chromatography. TLC were performed on fluorescent silica gel plates (60 F254 from Merck).
General procedure for the preparation of compounds 1-9
A solution of Na 2 CO 3 (2.5 equiv) in H 2 O (2 ml/mmol) was added to a suspension of bromide A (288 mg, 1.0 mmol) or J (302 mg, 1.0 mmol), the required boronic acid (1.1 equiv), Pd(PPh 3 ) 4 (57.8 mg, 5 mol %) in EtOH (3 ml/mmol) and toluene (3 ml/mmol). The reaction mixture was refluxed overnight under argon and the cooled resulting mixture was evaporated onto silica gel. Purification as indicated provided the desired compounds. 
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